Johnson & Johnson has reported positive phase 3 data with Darzalex in smouldering multiple myeloma, just before filing applications for the drug in this indication in Europe and the US.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.